An increasing percentage of autologous cells (increasing chimerism) in the whole blood (WB) chimerism test following allogeneic transplant is related to a very high risk of relapse. Preemptive immunotherapy may decrease the risk of relapse in some patients. Our prospective multiinstitutional study evaluated the feasibility of longitudinal chimerism testing in a central laboratory, compared WB, CD3 þ and leukemia-specific lineage chimerism in patients with a variety of hematologic malignancies, and evaluated the feasibility of fast withdrawal of immunosuppression based on WB chimerism results. Centralized chimerism testing was feasible and showed low interassay variability. Increasing mixed chimerism (MC) in WB was not useful as a predictor of relapse in our study. The presence of full donor chimerism in WB, CD3 þ and leukemia-specific lineages on all measurements was related to a significantly lower risk of relapse than the presence of MC in either subset (11 vs 71%, respectively; P ¼ 0.03). Increasing host chimerism in leukemia-specific lineage heralds relapse, but it was not detected early enough to allow immunotherapy. Further studies correlating lineage-specific chimerism and minimal residual disease are required. The goal of preemptive immunotherapy should be to achieve full donor chimerism in WB in CD3 þ and leukemia-specific lineages.
Introduction
Relapse of leukemia following hematopoietic cell transplant, which occurs in 20-40% of patients, remains the major cause of transplant failure. Coexistence of donor and host hematopoietic cells, called mixed chimerism (MC), and particularly an increasing proportion of host cells following allogeneic transplant for acute leukemia has been linked to the increased risk of relapse. [1] [2] [3] [4] [5] Although MC may predict relapse, detecting residual host cells after transplant, is not equivalent to detecting minimal residual disease. In the early post-transplant period, MC is caused predominantly by normal recipient hematopoietic cells. 6 It is hypothesized that a state of MC induces tolerance that may facilitate the proliferation of the remaining malignant cells. 6 In 1999, Bader et al. 3 showed that intervention consisting of cessation of immunosuppression followed by donor lymphocyte infusions, instituted upon the detection of increasing host chimerism, may decrease the risk of relapse in children with acute leukemia. Since then, a number of European studies have described the use of whole blood (WB) chimerism testing as the basis for initiating immunologic intervention. [2] [3] [4] [7] [8] [9] Several studies examining lineagespecific chimerism have been published as well, suggesting that the presence of an autologous signal in leukemiaspecific lineage chimerism testing may be a sensitive indicator of minimal residual disease. [10] [11] [12] [13] [14] Although most studies agree that the presence of MC following myeloablative transplantation for hematologic malignancies is related to an increased risk of relapse, not all authors could reliably identify 'increasing chimerism', 10 and not all authors agree that the preemptive immunotherapy based on chimerism testing improves clinical outcome. 15 The ability to determine increasing chimerism may depend on the frequency of chimerism testing, the amount of T cells in the specimen, definition of 'increasing chimerism' and whether the determination was made prospectively vs retrospectively.
Our prospective multi-institutional study was designed to test the feasibility of longitudinal testing in a central immunogenetic laboratory to compare WB, CD3 þ and leukemia-specific lineage chimerism in patients with a variety of hematologic malignancies, and to evaluate the feasibility of fast withdrawal of immunosuppression based on WB chimerism results.
Patients and methods

Enrollment eligibility criteria
The study was conducted in four United States institutions and enrolled 20 children with the diagnoses of acute leukemia in 17 patients (AML, ALL and biphenotypic leukemia), preleukemic syndromes in one patient (monosomy 7 or other BM clonal malformations, myelodysplastic syndrome) and juvenile myelomonocytic leukemia in two patients. Patients underwent related or unrelated allogeneic transplant following a myeloablative conditioning regimen. Three groups of conditioning regimens conferred study eligibility. The first one was based on TBI-a minimum of 1200 cGy combined with CY (120 mg/kg), and/or etoposide (60 mg/kg); the second one was based on the use of fulldose BU (equivalent of 16 mg/kg) in combination with fludarabine (160 mg/sq m) or CY (120-200 mg/kg) and/or melphalan (140 mg/sq m); the third one was based on the use of melphalan (a minimum of 140 mg/sq m), fludarabine (150 mg/sq m) and rATG (rabbit antithymocyte globulin; 8 mg/kg).
Any stem cell source (cord blood, BM or peripheral blood stem cells) was allowed, assuming that the donor's cells were available for post-transplant chimerism testing. Donor and recipient had to be matched at a minimum of 7/8 antigens (A, B, C and DRB1) for BM and peripheral blood SCT and X4/6 antigens (A, B and DRB1) for cord blood transplants.
Chimerism testing
Chimerism was determined using a semiquantitative PCRbased method involving amplification of genes containing short tandem repeats. For each donor-recipient pair, informative alleles were determined for a panel of short tandem repeat loci (CSFR, VWF, D21S11, D11S1294, D18S51, D16S486, D4S243, AMGY/AMGXA, HUMFI-BRA, PENTA D and PENTA E). If multiple loci were informative, two loci were selected for post-transplant testing for each donor-recipient pair. A peripheral blood mononuclear cell fraction was prepared for all patients using a Ficoll-Hypaque gradient. Cell subsets were isolated using Miltenyi magnetic particles (Miltenyi Biotec, Bergisch Gladbach, Germany) to select the desired subset from the peripheral blood mononuclear cells. For peripheral blood specimens, cells were selected based upon CD3 þ , CD14/ 15 þ and CD19 þ expressions. For BM specimens, CD33 þ and CD34 þ subsets were also analyzed. The purity of selected cells was checked using flow cytometry. DNA was isolated from WB or specific cell subsets using spin columns containing a silicagel membrane (QIAgen, Valencia, CA, USA). The size of the amplified fragments was determined using an automated nucleotide sequencer (Applied Biosystems, Foster City, CA, USA) and the quantity of each PCR product was determined using peak areas. Standard curves constructed using donor and recipient DNA were used to correct for technical factors, such as preferential amplification, which can influence the result. 16 To control for interassay variability, two longitudinal specimens were compared in each assay. Each sample was tested in duplicate for two informative loci.
Chimerism definitions
Full donor chimerism. X99% donor cells.
Mixed chimerism. o99% donor cells.
Significant change in chimerism on longitudinal testing. A change in the percentage of host signal was considered significant, if the difference in percentage donor cells exceeded the sensitivity of the assay. The sensitivity of the assay was dependent on the percentage of donor cells. If the donor cells were 95-99%, the assay sensitivity was 1%; for 90-94% donor cells, the sensitivity was 3% and for 11-89% donor cells, the sensitivity of the assay was 6%.
Chimerism trends
Stable mixed chimerism. Presence of host cell signal on longitudinal testing, which did not change significantly from the previous test.
Decreasing chimerism. Significant decrease in the amount of host signal on longitudinal testing.
Increasing chimerism. Significant increase in the amount of host signal on longitudinal testing.
Transient chimerism trend. If the trend of chimerism was not sustained over 2-3 consecutive measurements, the trend was considered transient. For example, finding increasing host chimerism on one test, followed by decreasing host chimerism on a subsequent test, followed by stable or increasing host chimerism on the next test would be considered transient chimerism trend.
Chimerism assessment
Chimerism testing on peripheral blood started at day þ 30, assuming that the absolute neutrophil count was more than 500 for 3 days. Testing was continued on study with a frequency of every 14-90 days for 1 year following the transplant, after which patients returned to their routine chimerism testing, as determined by each participating institution. For each peripheral blood specimen, chimerism testing was performed on whole blood, CD3 þ and leukemia-specific lineage subset (CD3 þ , CD14/15 þ or CD19 þ ). For BM specimens, CD33 þ and CD34 þ subsets were analyzed as well. We considered CD3 þ and CD19 þ subsets as lineage-specific markers for T-and B-cell ALL and CD14/15 þ and CD33 þ as a lineagespecific marker for myeloid malignancies. If 100% donor chimerism was detected in all subsets, the test was repeated at 3, 6, 9 and 12 months posttransplant. If X1% of host cells were detected in any of the subsets, chimerism testing was repeated every 2 weeks until either 100% donor chimerism or a trend of increasing chimerism in WB was documented. If increasing host chimerism in any subset was found, or if a patient with previously 100% donor cells developed MC, a BM specimen was obtained for chimerism testing and relapse detection. Chimerism testing was also performed on any BM specimen obtained for other reasons, such as protocol compliance or institutional standard of care. As a part of feasibility evaluation, we tracked whether samples were collected within 7 days of study-defined collection date as outlined in the study. The study-required collection date ±7 days was defined as 'target time' for submitting the specimen.
Preemptive fast withdrawal of immunosuppression
We used the results of WB chimerism as a basis for preemptive fast withdrawal of immunosuppression in patients who were still receiving prophylactic immunosuppression. Patients with documented increasing chimerism in WB who were in morphologic remission (defined as o5% blasts on BM examination) were eligible for fast withdrawal of immunosuppression. Patients with active GVHD, history of acute GVHD of grade X3 or history of chronic GVHD with multiple organ involvement were excluded from immunotherapy. Fast withdrawal of immunosuppression consisted of decreasing immunosuppression (usually CsA or tacrolimus) by 50% as soon as the patient was diagnosed with increasing chimerism on WB specimen. Immunosuppression was stopped 7 days later, if there was no evidence of GVHD. This study did not provide specific guidelines for the use of donor lymphocyte infusion (DLI) based on chimerism results, as we estimated that because of the small number of patients who would be eligible for DLI, meaningful data could not be gathered. Patients who received immunotherapy at the discretion of the treating physician and without documentation of increasing WB chimerism continued to be followed for toxicity of immunotherapy. However, they were not evaluated in the analysis of correlation between chimerism and leukemia relapse.
Acute and chronic GVHD were graded using the published criteria. 17, 18 Statistical analysis EFS was calculated using Kaplan-Meier analysis from the time of transplant, until the last contact for living patients or date of event (death or relapse). We used the Fisher's exact test with two-sided P-values for the comparison of categorical variables. All data analyses were performed using the SPSS statistical program (SPSS Inc., Chicago, IL, USA). Table 1 describes characteristics of 20 patients enrolled in this prospective multi-institutional study. The median age at enrollment in this study was 11 years (range: 1.2-21.5 years). The diagnoses included myeloid malignancy in 55% of patients and lymphoid malignancy in 45%. Ten patients received stem cells from a related donor and 10 patients Table 1 Characteristics of patients Chimerism testing and preemptive immunotherapy in children B Horn et al received stem cells from unrelated donors. The majority of patients received peripheral blood progenitor cells (65%), the remainder received cord blood (20%) or BM (15%) as a stem cell source. Eight patients (40%) received TBI-based conditioning regimens, 10 (50%) received BU-based conditioning and two (10%) patients received melphalan/ fludarabine/rATG conditioning. The majority of patients (80%) received CsA/MTX for GVHD prophylaxis, whereas the remainder received tacrolimus/MTX or tacrolimus with mycophenolate mofetil and rATG for GVHD prophylaxis. Median follow-up of living patients was 21 months (range: 16-31 months).
Results
Patient characteristics
Two patients (10%) died from transplant-related complications. Six patients (30%) relapsed; three of them died of their malignant disease and three are alive and undergoing therapy for relapse. The estimated EFS was 56 ± 12% (s.e.) at 2-years post transplant.
Feasibility of chimerism testing
We evaluated 154 peripheral blood specimens and 11 BM specimens. It took an average of 8 ± 2 (s.d.) working days from the time when the specimen was obtained until the referring institution received the results of chimerism testing. Seventy-two percent of specimens were submitted within study defined collection times, 12% were submitted sooner than the target time and 16% later than the target time. We analyzed 299 peripheral blood subsets (CD3 þ , CD14/15 þ and CD19 þ ) for the purity of magnetic bead separation. In 56/299 (19%) specimens, the purity was o95%, and in 35/299 (12%), the purity could not be determined, usually because of the low number of cells. We analyzed the reproducibility of chimerism testing as each DNA specimen was run at two different time points to control for interassay variability. In 334/345 specimens (97%), there was p1% difference between the two longitudinal runs, in 8/345 (2%) specimens there was 2% difference between the two longitudinal runs and in 3/345 (1%) of assays, there was 42% difference between the two separate runs.
Peripheral blood chimerism testing results
Post-transplant chimerism trends are described in detail in Table 2 .
Whole blood chimerism
Thirteen patients out of 20 (65%) had X99% donor cells on all WB longitudinal chimerism tests, whereas 7/20 (35%) patients had MC, only one of which qualified as increasing chimerism (patient 19). MC was detected on the first chimerism test in 5/7 patients, and on subsequent testing in 2/7 patients.
CD3 þ chimerism
Ten out of twenty patients (50%) developed MC in the CD3 þ subset, three of whom had increasing chimerism. In 9/10 patients, MC was detected on the first chimerism test and in 1/10, it appeared at 3 months post transplant. Leukemia-specific lineage chimerism Lineage-specific peripheral blood chimerism testing indicated X99% donor cells on all longitudinal chimerism tests in 17/20 (85%) patients. Two out of three patients with MC in leukemia-specific lineage had increasing chimerism detected concomitantly with relapse. In one patient (no. 7), MC in leukemia-specific lineage preceded relapse by 4 months. Table 3 shows the risk of relapse based on the presence of X99% donor cells, as opposed to o99% donor cells in WB, CD3 þ and leukemia-specific lineage. Four patients were excluded from this analysis (patient1 because of short follow-up, and patients 4, 6 and 20 as they received preemptive immunotherapy based on the persistence of MC rather than documented increasing chimerism in WB). Only leukemia-specific lineage MC showed correlation with relapse (Fisher's exact P ¼ 0.04). Patients with X99% donor's cells on all measurements in WB, CD3 þ and lineage-specific subset had lower risk of relapse (11%) than those with o99% donor cells in either subset (71%) (Fisher's exact P ¼ 0.03). The only patient who relapsed despite having full donor chimerism in all subsets (patient 14) developed mediastinal disease 9 months post transplant. At the time of relapse, BM showed no evidence of minimal residual disease by flow cytometry.
Chimerism and risk of relapse
BM vs peripheral blood chimerism testing
Seven pairs of chimerism tests were performed simultaneously from peripheral blood and BM in patients who were in morphologic remission at the time of testing. In four of these pairs, the results of BM and peripheral blood chimerism testing were within one percentage point. These four patients had X99% donor engraftment in WB and lineage-specific subsets, and none of them relapsed. In one patient, (patient 4) peripheral blood chimerism was lower than BM chimerisim, and this patient did not relapse. In two other BM-peripheral blood pairs, both from patient 7
(B-cell ALL), peripheral blood chimerism was 98% on both tests and 98 and 95% on BM, respectively. Peripheral blood CD19 þ chimerism was 99% on both tests, whereas simultaneously obtained BM chimerism showed 94 and 93% donor's cells, respectively.
Fast withdrawal of immunosuppression and DLI
None of the patients qualified for preemptive fast withdrawal of immunosuppression based on increasing chimerism on WB testing. Only one patient (patient 19) showed increasing WB chimerism at 1.5 months post transplant; however, this patient already had leukemia relapse at the time when increasing WB chimerism was documented.
Because of persistent MC in WB and CD3 þ subset, at the discretion of the treating physician, two patients received preemptive DLI (5 Â 10 6 /kg of G-CSF-mobilized CD3 þ cells) after they had already been tapered off immunosuppression, and one patient (patient 6) underwent fast withdrawal of immunosuppression at 3 months post transplant. All three patients who underwent preemptive immunotherapy showed stable or transient chimerism trend in WB and CD3 þ lineage; however, their lineage-specific chimerism was X99% donor on all tests. All three patients are alive without the evidence of disease. Three other patients (patients 5, 7 and 19) received intervention at the discretion of their treating physician, after their BM examination showed blasts (5, 1.5 and 8% blasts, respectively). All three patients died of progressive disease. Out of six patients undergoing immunotherapy, only one developed GVHD. Patient 5, following leukemia relapse, received 1 Â 10 8 /kg of nonmobilized CD3 þ and developed grade I acute and localized chronic GVHD correlating with transient leukemia remission.
Discussion
In 1998, Bader et al. 1 suggested that increasing chimerism post transplant can predict relapse. Ninety percent of 5 The detection of MC preceded relapse by a median of 74 days. A number of studies attempted preemptive intervention with fast withdrawal of immunosuppression and/or donor lymphocyte infusions in patients with documented increasing chimerism. 2, [7] [8] [9] In patients with increasing chimerism, fast withdrawal of immunosuppression resulted in long-term response in 9/14 children with ALL, 3/7 children with AML, 0/11 children with myelodysplastic syndrome and 0/2 patients with juvenile myelomonocytic leukemia. 2, [7] [8] [9] Use of DLI resulted in the long-term response in 5/20 children with ALL, 9/11 children with myelodysplastic syndrome, 1/6 children with juvenile myelomonocytic leukemia and 2/9 children with AML. 2, [8] [9] [10] Data in adults with AML showed that all 32 patients with increasing chimerism relapsed despite receiving immunomodulating therapy; 15 however, 4/8 patients with ALL who received DLI for MC showed long-term remission. 19 In 2000, Zetterquist et al.
13 evaluated lineage-specific (CD19 þ ) chimerism in children with B-cell ALL. They showed that lineage-specific chimerism correlated well with molecular confirmation of minimal residual disease and was detectable 2.5 months before morphologic relapse. 13 Similarly, Mattson et al. 11 showed that MC in CD13 þ and/or CD33 þ lineage in patients with AML could be detected a median of 66 days before hematologic relapse.
Our prospective study was designed to test the feasibility of longitudinal testing in a central laboratory to compare WB, CD3 þ and lineage-specific chimerism in patients with a variety of hematologic malignancies and to evaluate the feasibility of fast withdrawal of immunosuppression based on WB chimerism results.
We confirmed that chimerism testing in a central laboratory is feasible, the interassay variability is very low, and that puritiy of cell separation should be considered when evaluating chimerism in cell subsets. In early post-transplant samples, purity of cell separation is frequently low in CD3 þ and CD19 þ subsets, because of low absolute counts in those subsets. Unlike earlier studies, we observed an unexpectedly low incidence of prospectively detected increasing WB chimerism (5%). Several factors might have been responsible for this. First, our definition of increasing chimerism was based on the finding that a change between two longitudinal specimens that exceeded assay sensitivity, rather than the percentage increase in autologous signal, as published previously. [2] [3] [4] [5] [7] [8] [9] Second, the frequency of testing in our study was every 14 days in patients with MC, rather than weekly as in other reports.
2,7-9 Third, our samples might have contained a higher proportion of lymphocytes, as all of our patients received T-cell replete transplants, and 65% of our patients received peripheral blood stem cells. In some patients, we observed significant fluctuations in CD3 þ chimerism, which can occur because of an expansion of lymphocyte clones upon antigen stimulation. This may have affected the trend of the WB chimerism test. On the basis of our definition of increasing chimerism in WB, no patient qualified for immunologic intervention before documented relapse.
Full donor chimerism on all measurements in WB, CD3 þ and leukemia-specific lineage defined a group of patients who are not at risk of BM relapse. The presence of MC in the leukemia-specific lineage was predictive of relapse. Unfortunately, increasing chimerism in the leukemia-specific lineage was detected concomitantly with relapse and was not responsive to immunotherapy. The presence of MC in the CD3 þ lineage in patients who have hematologic malignancies other than T-cell leukemia does not predict relapse; however, it may indicate a state of immunologic tolerance permitting leukemia recurrence. Increasing chimerism in WB may result from an increase in the proportion of host cells in any of the subsets. The CD3 þ subset is most likely to contribute to the change in WB chimerism, as it shows the most fluctuations over time (data not shown). These fluctuations are often caused by the expansion of clones because of infections.
Despite a number of studies published over the last 10 years indicating that chimerism is useful in predicting relapse, chimerism testing has not been widely accepted in the United States as a basis for post-transplant intervention. This is likely related to a number of factors, including difficulties in interpreting changes in WB chimerism and their relationship to relapse, 20 the cost of frequent chimerism tests, particularly when subsets are obtained, availability of flow cytometry for minimal residual disease detection, 21 lack of options for post-transplant interventions and toxicities of available therapies, such as donor lymphocyte infusions. There have been significant changes in techniques for chimerism testing over time, from the variable number of tandem repeats to short tandem repeats and currently the single nucleotide polymorphism. The new techniques have resulted in increased sensitivity for detecting residual host cells. 22, 23 Presently, there are no adequate clinical data indicating that the increased sensitivity in detection of residual host cells improves the ability of chimerism tests to predict the relapse. The most sensitive test, if applied to WB, will also detect the fluctuations in CD3 þ subset, which may not be relevant to relapse.
Conclusions
Post-transplant subset chimerism testing in a centralized laboratory is feasible. Increasing MC in WB was not useful as a predictor of relapse in our study. However, limitations of our study include small patient number and a variety of malignancies studied. A larger study may find that changes in WB chimerism are useful in predicting relapse, or that the role of chimerism testing in predicting relapse may be disease-specific. Increasing MC in leukemia-specific lineage heralds relapse but was not detected early enough to allow intervention. Patients with full donor chimerism in WB, CD3 þ and leukemia-specific lineage have the lowest risk of relapse.
In future studies, we will attempt to correlate minimal residual disease and leukemia lineage-specific chimerism. Instead of relying on longitudinal chimerism testing, which requires significant resources and may delay intervention, we will base our decision making about immunotherapy on the presence of lineage-specific MC in the early posttransplant course or persistence of MC in WB and CD3 þ subset. The goal of preemptive immunotherapy will be to achieve full donor chimerism in all subsets. 
